×

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

  • US 10,662,233 B2
  • Filed: 12/13/2019
  • Issued: 05/26/2020
  • Est. Priority Date: 04/24/2015
  • Status: Active Grant
First Claim
Patent Images

1. A method of eliciting an immune response in a patient who has lung cancer overexpressing an MMP12 polypeptide comprising the amino acid sequence of SEQ ID NO:

  • 24, comprising administering to said patient a population of activated T cells that kill cancer cells,wherein the activated T cells are cytotoxic CD8+ T cells produced by contacting T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO;

    24 in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×